PE20131351A1 - Formas en estado solido de un potente inhibidor del vch - Google Patents

Formas en estado solido de un potente inhibidor del vch

Info

Publication number
PE20131351A1
PE20131351A1 PE2013000628A PE2013000628A PE20131351A1 PE 20131351 A1 PE20131351 A1 PE 20131351A1 PE 2013000628 A PE2013000628 A PE 2013000628A PE 2013000628 A PE2013000628 A PE 2013000628A PE 20131351 A1 PE20131351 A1 PE 20131351A1
Authority
PE
Peru
Prior art keywords
compound
methyl
mixture obtained
inhibitor
refers
Prior art date
Application number
PE2013000628A
Other languages
English (en)
Inventor
Rolf-Stefan Brickl
Shirlynn Chen
Jihchin Chung
Mayur Suryakant Dudhedia
Danping Li
Siddharthya Mujumdar
Chitra Telang
Richard J Varsolona
Zeren Wang
Zhi-Hui Lu
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44759789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131351(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20131351A1 publication Critical patent/PE20131351A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UNA SAL CRISTALINA DE SODIO DEL COMPUESTO DE FORMULA (1) QUE ES EL ACIDO (E)-3-[2-(1-{[2-(5-BROMO-PIRIMIDIN-2-IL)-3-CICLOPENTIL-1-METIL-1H-INDOL-6-CARBONIL]-AMINO}-CICLOBUTIL)-3-METIL-3H-BENCIMIDAZOL-5-IL]-ACRILICO CUYO MODELO DE DIFRACCION DE RAYOS X EN POLVO COMPRENDE PICOS DE 5.2, 7.5, 8.4, 13.1, 18.3, 20.0, 20.4, 21.4, 23.1 Y 25.4 GRADOS 2O QUE SE MIDE USANDO RADIACION CuKa. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION QUE COMPRENDE: i) HACER REACCIONAR EL COMPUESTO (1) CON UNA DISOLUCION DE NaOH ACUOSA EN UN DISOLVENTE ADECUADO, ii) ANADIR METIL-ETILCETONA A LA MEZCLA OBTENIDA EN LA ETAPA (i) MIENTRAS SE CALIENTA LA MEZCLA A UNA TEMPERATURA DE 50 A 60 °C, iii) ANADIR METIL-ETILCETONA ADICIONAL A LA MEZCLA OBTENIDA A UNA TEMPERATURA DE 50 °C, Y iv) ENFRIAR LA MEZCLA OBTENIDA A 25 °C, DANDO COMO RESULTADO LA PRECIPITACION DE CRISTALES DE LA SAL DE SODIO DEL COMPUESTO (1). DICHO COMPUESTO ES UN INHIBIDOR DE LA ARN POLIMERASA DEPENDIENTE DEL ARN DE NS5B DEL VIRUS DE LA HEPATITIS C (VHC) SIENDO UTIL EN EL TRATAMIENTO DE LA INFECCION POR VHC
PE2013000628A 2010-09-30 2011-09-23 Formas en estado solido de un potente inhibidor del vch PE20131351A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38824210P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
PE20131351A1 true PE20131351A1 (es) 2013-12-04

Family

ID=44759789

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000628A PE20131351A1 (es) 2010-09-30 2011-09-23 Formas en estado solido de un potente inhibidor del vch

Country Status (21)

Country Link
US (2) US8598183B2 (es)
EP (1) EP2621921A1 (es)
JP (1) JP2013543495A (es)
KR (1) KR20130108326A (es)
CN (1) CN103153987A (es)
AP (1) AP2013006733A0 (es)
AR (1) AR083256A1 (es)
AU (1) AU2011307346A1 (es)
BR (1) BR112013007700A2 (es)
CA (1) CA2813179A1 (es)
CL (1) CL2013000578A1 (es)
CO (1) CO6700844A2 (es)
EA (1) EA201300422A1 (es)
EC (1) ECSP13012552A (es)
MA (1) MA34548B1 (es)
MX (1) MX2013003551A (es)
PE (1) PE20131351A1 (es)
SG (1) SG188376A1 (es)
TW (1) TW201307327A (es)
UY (1) UY33632A (es)
WO (1) WO2012044520A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013007700A2 (pt) * 2010-09-30 2019-09-24 Boehringer Ingelheim Int formas em estado sólido de um potente inibidor de hcv
AR089078A1 (es) * 2011-12-06 2014-07-30 Sanofi Sa Formas cristalinas de [(s)-1-carbamoil-2-(fenil-pirimidin-2-il-amino)-etil]-amida de acido 2-(2-metilamino-pirimidin-4-il)-1h-indol-5-carboxilico
US20130261134A1 (en) * 2012-03-30 2013-10-03 Boehringer Ingelheim International Gmbh Mesylate salt forms of a potent hcv inhibitor
WO2014138374A1 (en) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Oral combination therapy for treating hcv infection in specific patient sub-population

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69426408T2 (de) 1993-09-28 2001-07-12 Scherer Gmbh R P Herstellung von Weichgelatinekapseln
US5821242A (en) * 1996-06-06 1998-10-13 Eli Lilly And Company Anti-viral compounds
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
ES2431314T3 (es) 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Inhibidores de polimerasa vírica
AU2006213769B2 (en) 2005-02-11 2012-10-04 Boehringer Ingelheim International Gmbh Process for preparing 2,3-disubstituted indoles
JP5284101B2 (ja) 2005-11-09 2013-09-11 ノバルティス アーゲー 一時可塑剤を用いる医薬組成物の製造法
BR112013007700A2 (pt) * 2010-09-30 2019-09-24 Boehringer Ingelheim Int formas em estado sólido de um potente inibidor de hcv

Also Published As

Publication number Publication date
EA201300422A1 (ru) 2013-09-30
CA2813179A1 (en) 2012-04-05
WO2012044520A1 (en) 2012-04-05
CL2013000578A1 (es) 2013-08-02
EP2621921A1 (en) 2013-08-07
AR083256A1 (es) 2013-02-13
SG188376A1 (en) 2013-04-30
UY33632A (es) 2012-04-30
CN103153987A (zh) 2013-06-12
JP2013543495A (ja) 2013-12-05
ECSP13012552A (es) 2013-06-28
TW201307327A (zh) 2013-02-16
KR20130108326A (ko) 2013-10-02
US8598183B2 (en) 2013-12-03
US20140057928A1 (en) 2014-02-27
AU2011307346A1 (en) 2013-02-21
US20120122887A1 (en) 2012-05-17
MA34548B1 (fr) 2013-09-02
CO6700844A2 (es) 2013-06-28
AP2013006733A0 (en) 2013-02-28
MX2013003551A (es) 2013-05-01
BR112013007700A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
ES2660773T3 (es) Procedimiento para la preparación de una sal cristalina trialcalino-metálica de L-MGDA
PE20141423A1 (es) Derivados nucleosidos con sustitucion 2',4'-difluoro-2'-metilo como inhibidores de la replicacion del arn del vhc
AR073298A1 (es) Formas cristalinas del 2-tiazolil-4-quinolil-oxi amidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la infeccion por hcv.
JP2016523906A5 (es)
AR087683A1 (es) N-[1-((6-cloropiridin-3-il)metil)piridin-2-(1h)-ilideno]-2,2,2-trifluoroacetamida, metodo para su preparacion y un intermediario para su sintesis
PE20131351A1 (es) Formas en estado solido de un potente inhibidor del vch
WO2014128545A3 (en) An improved process for the preparation of dolutegravir
AR083873A1 (es) Derivados de acido amino-fenil-pentanoico sustituidos como inhibidores de nep
AR073892A1 (es) Proceso de preparacion de inhibidores de sglt
UA108221C2 (uk) Похідні тіофен-2-карбонової кислоти як інгібітори вірусів flaviviridae
PE20120995A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
EP3056486A3 (en) Process for preparing intermediates for antiviral compounds
PE20141325A1 (es) Preparacion de gadobutrol de alta pureza
AR091431A1 (es) Compuestos de acido dimetil-benzoico
AR098107A1 (es) Proceso para la preparación de 3-(3-cloro-1h-pirazol-1-il)piridina
AR085856A1 (es) Formas cristalinas del acido (2s)-2-ter-butoxi-2-(4-(2,3-dihidropirano[4,3,2-de]quinolin-7-il)-2-metilquinolin-3-il)acetico
RU2014145481A (ru) Циклопропанкарбоксилатные эфиры пуриновых аналогов
RU2015142819A (ru) Натриевая соль (2s, 5r)-6-бензилокси-7-оксо-1,6-диаза-бицикло[3.2.1]октан-2-карбоновой кислоты и ее получение
MX2013003227A (es) Nuevos analogos de piperazina con grupos heteroarilo sustituidos como antivirales de la influenza de espectro amplio.
IN2012DN06678A (es)
NZ610765A (en) Method for the preparation of high-purity pharmaceutical intermediates
BR112014009266A8 (pt) processos encurtado, biocatalítico e para preparação de ácidos isoxazolil-metóxi-nicotínicos
EA201270798A1 (ru) Соединения для лечения гепатита с
HRP20161186T1 (hr) Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama
WO2021016670A1 (en) Antiviral agents and uses thereof

Legal Events

Date Code Title Description
FD Application declared void or lapsed